四例新发骨质疏松-假性胶质瘤综合征患者:鉴定两种新型LRP5变异并探讨双膦酸盐治疗管理
该研究报道了来自埃及的四例骨质疏松-假性胶质瘤综合征(OPPG)患者的临床、影像学及分子数据,并评估其对口服和静脉双膦酸盐治疗的反应。所有患者骨密度降低伴多发骨折及特征性眼部表型,LRP5基因分析发现三种纯合变异,包括两种新型变异c.7delG(p.A3Qfs*80)和c.3280G>A(p.E1094K)。双膦酸盐治疗有益,静脉给药反应更佳。
要点
- 四例OPPG患者均表现为骨密度降低、多发骨折及特征性眼部表型。
- LRP5基因检出三种纯合变异,其中c.7delG和c.3280G>A为新型变异。
- 双膦酸盐治疗有益,静脉给药反应优于口服给药。
核心结论
- 本研究描述了四例OPPG患者的表型和遗传特征,并鉴定出两种新型LRP5变异,扩展了OPPG的突变谱。
- 本研究强化了使用静脉双膦酸盐治疗OPPG患者的有效性。
研究设计与样本
- 研究报道了来自埃及的四例新发OPPG患者的临床、影像学和分子发现。
- 研究评估了患者对口服和静脉双膦酸盐治疗的反应。
主要发现
- 所有患者骨密度降低,每年骨折次数不一,并伴有骨骼异常和OPPG特征性眼部表型。
- LRP5基因突变分析发现三种不同的纯合变异,包括两种新型变异c.7delG(p.A3Qfs*80)和c.3280G>A(p.E1094K)。
- c.3280G>A(p.E1094K)在两例无亲缘关系患者中重复出现,且共享独特单倍型,提示可能存在奠基者效应。
- 双膦酸盐治疗有益,但静脉给予双膦酸盐导致更有利的反应。
临床怎么用
- 作者认为静脉双膦酸盐在OPPG患者管理中有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study describes the clinical, radiological, and molecular data of four new patients with osteoporosis-pseudoglioma syndrome and assesses their response to bisphosphonate therapy. INTRODUCTION: Osteoporosis-pseudoglioma syndrome (OPPG) is a very rare disorder characterized mainly by severe juvenile osteoporosis and congenital blindness. OPPG is caused by biallelic mutations in the gene encoding low-density lipoprotein receptor-related protein 5 (LRP5). METHODS: We present the clinical, radiological, and molecular findings of four new patients with OPPG from Egypt. We also assessed patients' response to oral and intravenous bisphosphonate therapy. RESULTS: All patients had reduced bone mineral density (BMD) with variable number of fractures per year, in addition to bone abnormalities and the characteristic eye phenotype associated with OPPG. Mutation analyses of LRP5 gene revealed three different homozygous variants including two novel ones, c.7delG (p.A3Qfs*80) and c.3280G > A (p.E1094K). The c.3280G > A (p.E1094K) was recurrent in two unrelated patients who shared a unique haplotype suggesting a possible founder effect. The use of bisphosphonate therapy was beneficial; however, intravenous bisphosphonate administration led to a more favorable response. CONCLUSION: Our study described the phenotypic and genetic features of four patients with OPPG and identified two new LRP5 variants, thus expanding the mutational spectrum of OPPG. In addition, our study reinforces the efficiency of using intravenous bisphosphonates in the management of patients with OPPG.
引用
- Abdel-Hamid MS, Elhossini RM, Otaify GA, et al. Osteoporosis-pseudoglioma syndrome in four new patients: identification of two novel LRP5 variants and insights on patients' management using bisphosphonates therapy. Osteoporos Int. 2022. PMID: 35106624. doi:10.1007/s00198-022-06313-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。